Gemcitabine 1000 mg

DRUG6 trials

Sponsors

Incyte Corp., St. Petersburg State Pavlov Medical University, University Hospital Southampton NHS Foundation Trust, Loma Linda University, National Health Research Institutes, Taiwan

Conditions

Adenocarcinoma of the PancreasCholangiocarcinomaDiffuse Large B Cell LymphomaPancreas AdenocarcinomaPhase II, Open-label, Parallel 2-arm, Multi-centerRefractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell LymphomaResectable Pancreatic Cancer

Phase 1

Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

CompletedNCT03259529

St. Petersburg State Pavlov Medical UniversityDiffuse Large B Cell Lymphoma

Start: 2017-03-27End: 2020-01-27Updated: 2021-06-07

Phase 2

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

TerminatedNCT03422523

University Hospital Southampton NHS Foundation TrustDiffuse Large B Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma

Start: 2018-05-09End: 2021-11-18Updated: 2022-08-22

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

RecruitingNCT03492671

Loma Linda UniversityPancreas Adenocarcinoma, Resectable Pancreatic Cancer

Start: 2019-07-17End: 2026-09-30Target: 30Updated: 2025-10-02

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Active, not recruitingNCT05026905

National Health Research Institutes, TaiwanPhase II, Open-label, Parallel 2-arm, Multi-center

Start: 2021-12-28End: 2027-12-01Target: 66Updated: 2026-01-20

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

RecruitingNCT05821556

National Cancer Institute, NaplesAdenocarcinoma of the Pancreas

Start: 2023-06-12End: 2026-06-30Target: 240Updated: 2025-07-29

Phase 3

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

CompletedCTIS2024-513513-12-00

Incyte Corp.Cholangiocarcinoma

Start: 2019-01-06End: 2025-06-03Target: 110Updated: 2025-07-23

Related Papers

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

2024-09-195 citations